Streetbeat News

Revenues

PATH

UiPath (NYSE:PATH) received 9 analyst ratings in the last quarter with a spectrum of views. The average 12-month price target is $22.0, up 17.33% from the previous $18.75. Analysts from firms like Canaccord Genuity, JP Morgan, and RBC Capital have raised their price targets, reflecting optimism about the company's prospects. UiPath's financial health shows strong revenue growth but below-average profitability and efficiency metrics. The company's market capitalization is below the industry average, and it has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:00 pm

SPT

Sprout Social (NASDAQ:SPT) has been reviewed by 4 analysts, with all maintaining a 'Somewhat Bullish' stance and raising their 12-month price targets, averaging $68.00, up from the previous $55.33. The company shows strong revenue growth but struggles with profitability and efficiency, as indicated by a net margin of -26.91% and ROA of -6.35%. The firm's market cap is above industry average, and it has a conservative debt-to-equity ratio of 0.65.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:00 pm

ZI

ZoomInfo Technologies (NASDAQ:ZI) has been analyzed by 14 financial analysts, showing a range of opinions. The average 12-month price target is now $20.14, down from $24.86, with high and low estimates of $24.00 and $16.00, respectively. Analysts have adjusted their ratings and price targets, with many lowering their expectations. ZoomInfo's revenue growth is strong at 9.11%, with a net margin of 9.62% and an ROE of 1.31%, but its ROA of 0.42% is below industry benchmarks. The company's debt-to-equity ratio is healthy at 0.59.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 9:00 pm

SLAB

Analysts have provided mixed reviews on Silicon Laboratories (NASDAQ:SLAB) over the past three months, with 6 ratings ranging from bullish to indifferent. The average 12-month price target is now $132.67, down from $153.20, with a high estimate of $170.00 and a low of $86.00. Analysts from firms like Stifel, JP Morgan, Morgan Stanley, and Keybanc have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Silicon Laboratories develops solutions for various markets and has a market cap below the industry average. It experienced a revenue decline of -24.48% as of September 30, 2023, but has strong net margin, ROE, and ROA figures, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

PDD

PDD Holdings (NASDAQ:PDD) received 4 bullish analyst ratings in the latest quarter, with a 12-month average price target of $174.25, up from $145.50. Analysts from Benchmark and Goldman Sachs raised their price targets, reflecting positive sentiment based on the company's strong financial performance, including a 93.89% revenue growth rate, a 22.57% net margin, and an ROE of 10.11%. PDD Holdings operates a portfolio of businesses and aims to integrate more businesses into the digital economy.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

VAC

Marriott Vacations (NYSE:VAC) received mixed analyst ratings in the latest quarter, with 5 analysts offering a range of views. The average 12-month price target is $104.6, with a high of $149.00 and a low of $65.00, reflecting a 24.2% decrease in the average target. Analysts from Jefferies, B of A Securities, Truist Securities, and JP Morgan have adjusted their ratings and price targets, indicating a shift in sentiment. Marriott Vacations operates in the leisure industry, primarily in the US, with challenges in revenue growth, net margin, ROE, ROA, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:01 pm

EXAS

Exact Sciences (NASDAQ:EXAS) has been rated by 5 analysts in the past three months, with 3 bullish and 2 somewhat bullish ratings. The average 12-month price target is $88.2, with a high of $91.00 and a low of $80.00, marking a 7.16% decrease in the average target. Analysts from Benchmark, Guggenheim, Goldman Sachs, and Piper Sandler have provided recent evaluations, with some lowering their price targets. Exact Sciences, known for its cancer screening tests, shows a positive revenue trend but lags in growth rate compared to peers, has a strong net margin, but faces challenges in ROE and excels in ROA. The company maintains a prudent debt management with a debt-to-equity ratio of 0.82.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:00 pm

ARWR

Arrowhead Pharma (NASDAQ:ARWR) has been analyzed by 4 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $38.25, up from the previous $34.50. Analysts from B of A Securities and Morgan Stanley have adjusted their price targets, while RBC Capital maintains a high estimate. Arrowhead's financials indicate a market cap above industry average, a significant revenue decline, high net margin, and low ROE and ROA. The company has a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 8:00 pm

BNTX

MRNA

BioNTech shares are trading higher, potentially due to Moderna's expectation of increased vaccine sales in 2025 and a rise in respiratory virus activity that could boost vaccine demand.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 7:51 pm

BTCUSD

ETHUSD

SOLUSD

Bitcoin-based NFTs, known as Ordinals, reached a record $881M in sales in December 2023, a 130% increase from November. The Ordinals protocol allows unique data inscriptions on Bitcoin's blockchain, contributing to the market growth. The number of active buyers and sellers also hit record highs. Solana flipped Ethereum in monthly NFT sales for the first time, with $366M in sales compared to Ethereum's $353M. The performance of Bitcoin NFTs and the broader NFT market's resurgence could indicate a significant shift in the digital asset space.

Portfolio Pulse from Murtuza Merchant

January 02, 2024 | 7:10 pm